Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India’s Cipla Lines Up Foreign Governments For Its Tamiflu Generic

This article was originally published in PharmAsia News

Executive Summary

Cipla of India says it has reached an agreement to sell its generic version of Roche's Tamiflu (oseltamivir) to Mexico to treat the A/H1N1 flu virus. The World Health Organization has declared Cipla's Antiflu as effective as Roche's branded product. Cipla's head, Yusuf Hamled, said the company also is negotiating similar arrangements with several other countries in Africa, Latin America and the Middle East. Roche and Tamiflu's patent holder, Gilead, recently lost an Indian court case against the Cipla generic. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel